Literature DB >> 24060899

Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy.

Denise C Cornelius1, James P Hogg, Jeremy Scott, Kedra Wallace, Florian Herse, Janae Moseley, Gerd Wallukat, Ralf Dechend, Babbette LaMarca.   

Abstract

Preeclampsia, new onset hypertension with proteinuria during pregnancy, is associated with chronic inflammation and placental oxidative stress (ROS). Chronic interleukin-17 (IL-17) increases blood pressure, autoantibodies (angiotensin II type I receptor [AT1-AA]), and ROS during pregnancy. The objective of this study was to determine whether T-helper 17 (TH17) suppression via IL-17 recombinant receptor C (IL-17RC) decreases pathophysiology associated with placental ischemia (reduced uterine perfusion pressure [RUPP]). On gestation day 14, miniosmotic pumps infusing 100 pg of IL-17RC per day were implanted into pregnant rats undergoing RUPP. On gestation day 18, carotid catheters were inserted. On gestation day 19, mean arterial pressure was recorded and TH17 cells, oxidative stress, and AT1-AA were measured and analyzed via 1-way ANOVA. Mean arterial pressure increased from 101 ± 2 mm Hg in normal pregnant rats (n = 19) to 120 ± 1 mm Hg in RUPP rats (n = 17) but decreased to 110 ± 2 mm Hg in RUPP+IL-17RC rats (n = 22). Pup weight decreased from 2.28 ± 0.2 g in normal pregnant rats to 1.96 ± 0.3 g in RUPP rats but was significantly increased to 2.01 ± 0.1 in RUPP+IL-17RC rats. TH17 cells were 1.77% in RUPP rats but decreased to 0.65% in RUPP+IL-17RC rats. Urinary isoprostanes were normalized in RUPP+IL-17RC rats (52 pg/µg) compared with 89 pg/µg in RUPP controls. Placental ROS was 652 relative light units in RUPP rats but decreased to 337 relative light units in RUPP+IL-17RC rats. AT1-AA was 17.27 ± 0.7 bpm in RUPP rats but decreased to 5.00 ± 0.5 bpm in RUPP+IL-17RC rats. With this study, we show that infusion of IL-17RC blunts TH17s, oxidative stress, AT1-AA, and hypertension in the RUPP model of preeclampsia, indicating that TH17 cells may play an important role in disease pathophysiology.

Entities:  

Keywords:  hypertension; inflammation; oxidative stress; pregnancy

Mesh:

Substances:

Year:  2013        PMID: 24060899      PMCID: PMC3899693          DOI: 10.1161/HYPERTENSIONAHA.113.01514

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

Review 1.  Pathophysiology of pregnancy-induced hypertension.

Authors:  J P Granger; B T Alexander; W A Bennett; R A Khalil
Journal:  Am J Hypertens       Date:  2001-06       Impact factor: 2.689

2.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

Review 3.  Deciphering the role of Th17 cells in human disease.

Authors:  Cailin Moira Wilke; Keith Bishop; David Fox; Weiping Zou
Journal:  Trends Immunol       Date:  2011-09-28       Impact factor: 16.687

Review 4.  Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia.

Authors:  Ralf Dechend; Volker Homuth; Gerd Wallukat; Dominik N Müller; Manja Krause; Joachim Dudenhausen; Hermann Haller; Friedrich C Luft
Journal:  J Soc Gynecol Investig       Date:  2006-02

5.  The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy.

Authors:  Marc R Parrish; Sydney R Murphy; Sarah Rutland; Kedra Wallace; Katrin Wenzel; Gerd Wallukat; Sharon Keiser; Lillian Fournier Ray; Ralf Dechend; James N Martin; Joey P Granger; Babbette LaMarca
Journal:  Am J Hypertens       Date:  2010-04-29       Impact factor: 2.689

6.  Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes.

Authors:  Babbette LaMarca; Kedra Wallace; Florian Herse; Gerd Wallukat; James N Martin; Abram Weimer; Ralf Dechend
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

7.  IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection.

Authors:  Euan Lockhart; Angela M Green; JoAnne L Flynn
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

8.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

9.  Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats.

Authors:  Jeffrey Gilbert; Matt Dukes; Babbette LaMarca; Kathy Cockrell; Sara Babcock; Joey Granger
Journal:  Am J Hypertens       Date:  2007-06       Impact factor: 2.689

10.  Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.

Authors:  Brigitte Santner-Nanan; Michael John Peek; Roma Khanam; Luise Richarts; Erhua Zhu; Barbara Fazekas de St Groth; Ralph Nanan
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

View more
  60 in total

Review 1.  Dual opposing roles of adaptive immunity in hypertension.

Authors:  Noureddine Idris-Khodja; Muhammad Oneeb Rehman Mian; Pierre Paradis; Ernesto L Schiffrin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

2.  Interleukin-17 signaling mediates cytolytic natural killer cell activation in response to placental ischemia.

Authors:  Olivia K Travis; Dakota White; Cedar Baik; Chelsea Giachelli; Willie Thompson; Cassandra Stubbs; Mallory Greer; James P Lemon; Jan Michael Williams; Denise C Cornelius
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-22       Impact factor: 3.619

Review 3.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

4.  IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia.

Authors:  Ashlyn Harmon; Denise Cornelius; Lorena Amaral; Adrienne Paige; Florian Herse; Tarek Ibrahim; Gerd Wallukat; Jessica Faulkner; Janae Moseley; Ralf Dechend; Babbette LaMarca
Journal:  Hypertens Pregnancy       Date:  2015-05-21       Impact factor: 2.108

Review 5.  Inflammatory mediators: a causal link to hypertension during preeclampsia.

Authors:  Denise C Cornelius; Jesse Cottrell; Lorena M Amaral; Babbette LaMarca
Journal:  Br J Pharmacol       Date:  2018-09-28       Impact factor: 8.739

Review 6.  Inflammation, immunity, and hypertensive end-organ damage.

Authors:  William G McMaster; Annet Kirabo; Meena S Madhur; David G Harrison
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

Review 7.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

8.  Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia.

Authors:  Purvi Mehrotra; Jason A Collett; Susan J Gunst; David P Basile
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-14       Impact factor: 3.619

9.  Role of immune factors in angiotensin II-induced hypertension and renal damage in Dahl salt-sensitive rats.

Authors:  Brittany Wade; Galina Petrova; David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-08       Impact factor: 3.619

10.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.